Structure Therapeutics Inc. unveils oral obesity treatment pipeline in new corporate presentation

Reuters01-13

Structure <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. unveils oral obesity treatment pipeline in new corporate presentation

Structure Therapeutics Inc. released a corporate presentation detailing its current approach and pipeline in the development of oral small molecule treatments for obesity and related metabolic conditions. The company highlighted the significant unmet need for accessible obesity treatments worldwide, noting that current injectable GLP-1 therapies address less than 5% of the potential market in the United States. Structure Therapeutics is advancing several oral small molecule candidates, including the GLP-1 receptor agonist Aleniglipron, which is Phase 3 ready, and two amylin candidates (ACCG-2671 and ACCG-3535) in early-stage clinical development. The presentation emphasized the pharmacologic and economic advantages of oral small molecules over oral peptides, including ease of administration, combination potential, scalability, and cost benefits. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603928544?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 00:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603928544","market":"nz","top_or_hot":-1,"title":"Structure Therapeutics Inc. unveils oral obesity treatment pipeline in new corporate presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. unveils oral obesity treatment pipeline in new corporate presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Structure Therapeutics Inc. released a corporate presentation detailing its current approach and pipeline in the development of oral small molecule treatments for obesity and related metabolic conditions. The company highlighted the significant unmet need for accessible obesity treatments worldwide, noting that current injectable GLP-1 therapies address less than 5% of the potential market in the United States. Structure Therapeutics is advancing several oral small molecule candidates, including the GLP-1 receptor agonist Aleniglipron, which is Phase 3 ready, and two amylin candidates (ACCG-2671 and ACCG-3535) in early-stage clinical development. The presentation emphasized the pharmacologic and economic advantages of oral small molecules over oral peptides, including ease of administration, combination potential, scalability, and cost benefits. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Structure Therapeutics Inc. unveils oral obesity treatment pipeline in new corporate presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStructure Therapeutics Inc. unveils oral obesity treatment pipeline in new corporate presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 00:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. unveils oral obesity treatment pipeline in new corporate presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Structure Therapeutics Inc. released a corporate presentation detailing its current approach and pipeline in the development of oral small molecule treatments for obesity and related metabolic conditions. The company highlighted the significant unmet need for accessible obesity treatments worldwide, noting that current injectable GLP-1 therapies address less than 5% of the potential market in the United States. Structure Therapeutics is advancing several oral small molecule candidates, including the GLP-1 receptor agonist Aleniglipron, which is Phase 3 ready, and two amylin candidates (ACCG-2671 and ACCG-3535) in early-stage clinical development. The presentation emphasized the pharmacologic and economic advantages of oral small molecules over oral peptides, including ease of administration, combination potential, scalability, and cost benefits. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL8pb19B:1","article_id":"2603928544","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603928544","pubTimestamp":1768233951,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Structure Therapeutics Inc. released a corporate presentation detailing its current approach and pipeline in the development of oral small molecule treatments for obesity and related metabolic conditions. The company highlighted the significant unmet need for accessible obesity treatments worldwide, noting that current injectable GLP-1 therapies address less than 5% of the potential market in the United States. Structure Therapeutics is advancing several oral small molecule candidates, including the GLP-1 receptor agonist Aleniglipron, which is Phase 3 ready, and two amylin candidates  in early-stage clinical development. The presentation emphasized the pharmacologic and economic advantages of oral small molecules over oral peptides, including ease of administration, combination potential, scalability, and cost benefits. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. W","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","GPCR":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","BK4599":"减肥药"},"translate_title":"Structure Therapeutics Inc.在新的公司演示中推出口服肥胖治疗管道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GPCR":0.9},"content_text":"Structure Therapeutics Inc. unveils oral obesity treatment pipeline in new corporate presentation\n    \n\n        Structure Therapeutics Inc. released a corporate presentation detailing its current approach and pipeline in the development of oral small molecule treatments for obesity and related metabolic conditions. The company highlighted the significant unmet need for accessible obesity treatments worldwide, noting that current injectable GLP-1 therapies address less than 5% of the potential market in the United States. Structure Therapeutics is advancing several oral small molecule candidates, including the GLP-1 receptor agonist Aleniglipron, which is Phase 3 ready, and two amylin candidates (ACCG-2671 and ACCG-3535) in early-stage clinical development. The presentation emphasized the pharmacologic and economic advantages of oral small molecules over oral peptides, including ease of administration, combination potential, scalability, and cost benefits. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603928544","isCrawlerRequest":true}